- Home
- ROIV vs JAZZ Comparison
ROIV vs JAZZ Comparison
Compare ROIV & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROIV
- JAZZ
- Stock Information
- Founded
- ROIV 2014
- JAZZ 2003
- Country
- ROIV United Kingdom
- JAZZ Ireland
- Employees
- ROIV N/A
- JAZZ N/A
- Industry
- ROIV Biotechnology: Pharmaceutical Preparations
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- ROIV Health Care
- JAZZ Health Care
- Exchange
- ROIV Nasdaq
- JAZZ Nasdaq
- Market Cap
- ROIV 7.8B
- JAZZ 6.7B
- IPO Year
- ROIV N/A
- JAZZ 2007
- Fundamental
- Price
- ROIV $11.45
- JAZZ $107.51
- Analyst Decision
- ROIV Buy
- JAZZ Strong Buy
- Analyst Count
- ROIV 4
- JAZZ 12
- Target Price
- ROIV $17.50
- JAZZ $183.08
- AVG Volume (30 Days)
- ROIV 5.4M
- JAZZ 730.8K
- Earning Date
- ROIV 08-07-2025
- JAZZ 07-30-2025
- Dividend Yield
- ROIV N/A
- JAZZ N/A
- EPS Growth
- ROIV N/A
- JAZZ 49.21
- EPS
- ROIV N/A
- JAZZ 7.51
- Revenue
- ROIV $29,053,000.00
- JAZZ $4,064,808,000.00
- Revenue This Year
- ROIV $2.64
- JAZZ $6.05
- Revenue Next Year
- ROIV $378.09
- JAZZ $4.68
- P/E Ratio
- ROIV N/A
- JAZZ $14.35
- Revenue Growth
- ROIV N/A
- JAZZ 5.76
- 52 Week Low
- ROIV $8.73
- JAZZ $95.49
- 52 Week High
- ROIV $13.06
- JAZZ $148.06
- Technical
- Relative Strength Index (RSI)
- ROIV 57.83
- JAZZ 45.65
- Support Level
- ROIV $10.89
- JAZZ $106.56
- Resistance Level
- ROIV $11.79
- JAZZ $109.43
- Average True Range (ATR)
- ROIV 0.35
- JAZZ 2.66
- MACD
- ROIV 0.01
- JAZZ -0.16
- Stochastic Oscillator
- ROIV 62.57
- JAZZ 12.27
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.